RT Journal Article
SR Electronic
T1 Measurement of SARS-CoV-2 antigens in plasma of pediatric patients with acute COVID-19 or MIS-C using an ultrasensitive and quantitative immunoassay
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.08.21267502
DO 10.1101/2021.12.08.21267502
A1 Sigal, George B.
A1 Novak, Tanya
A1 Mathew, Anu
A1 Chou, Janet
A1 Zhang, Yubo
A1 Manjula, Navaratnam
A1 Bathala, Predeepthi
A1 Joe, Jessica
A1 Padmanabhan, Nikhil
A1 Romero, Daniel
A1 Allegri-Machado, Gabriella
A1 Joerger, Jill
A1 Loftis, Laura L.
A1 Schwartz, Stephanie P.
A1 Walker, Tracie C.
A1 Fitzgerald, Julie C.
A1 Tarquinio, Keiko M.
A1 Zinter, Matt S.
A1 Schuster, Jennifer E.
A1 Halasa, Natasha B.
A1 Cullimore, Melissa L.
A1 Maddux, Aline B.
A1 Staat, Mary A.
A1 Irby, Katherine
A1 Flori, Heidi R.
A1 Coates, Bria M.
A1 Crandall, Hillary
A1 Gertz, Shira J.
A1 Randolph, Adrienne G.
A1 Pollock, Nira R.
A1 on behalf of the Overcoming COVID-19 Investigators
YR 2021
UL http://medrxiv.org/content/early/2021/12/09/2021.12.08.21267502.abstract
AB Background Detection of SARS-CoV-2 antigens in blood has high sensitivity in adults with acute COVID-19, but sensitivity in pediatric patients is unclear. Recent data suggest that persistent SARS-CoV-2 spike antigenemia may contribute to multisystem inflammatory syndrome in children (MIS-C). We quantified SARS-CoV-2 nucleocapsid (N) and spike (S) antigens in blood of pediatric patients with either acute COVID-19 or MIS-C using ultrasensitive immunoassays (Meso Scale Discovery).Methods Plasma was collected from inpatients (<21 years) enrolled across 15 hospitals in 15 US states. Acute COVID-19 patients (n=36) had a range of disease severity and positive nasopharyngeal SARS-CoV-2 RT-PCR within 24 hours of blood collection. Patients with MIS-C (n=53) met CDC criteria and tested positive for SARS-CoV-2 (RT-PCR or serology). Controls were patients pre-COVID-19 (n=67) or within 24h of negative RT-PCR (n=43).Results Specificities of N and S assays were 95-97% and 100%, respectively. In acute COVID-19 patients, N/S plasma assays had 89%/64% sensitivity, respectively; sensitivity in patients with concurrent nasopharyngeal swab cycle threshold (Ct) ≤ 35 were 93%/63%. Antigen concentrations ranged from 1.28-3,844 pg/mL (N) and 1.65-1,071 pg/mL (S) and correlated with disease severity. In MIS-C, antigens were detected in 3/53 (5.7%) samples (3 N-positive: 1.7, 1.9, 121.1 pg/mL; 1 S-positive: 2.3 pg/mL); the patient with highest N had positive nasopharyngeal RT-PCR (Ct 22.3) concurrent with blood draw.Conclusions Ultrasensitive blood SARS-CoV-2 antigen measurement has high diagnostic yield in children with acute COVID-19. Antigens were undetectable in most MIS-C patients, suggesting that persistent antigenemia is not a common contributor to MIS-C pathogenesis.Key points In a U.S. pediatric cohort tested with ultrasensitive immunoassays, SARS-CoV-2 nucleocapsid antigens were detectable in most patients with acute COVID-19, and spike antigens were commonly detectable. Both antigens were undetectable in almost all MIS-C patients.Competing Interest StatementG.B.S., A.M., N.M., P.B, J.J., N. P., and D.R. are employees of Meso Scale Diagnostics. N.R.P., J.C., T.N., Y.Z., G.A.M., J.J., A.G.R., S.P.S., T.C.W., K.M.T., M.S.Z., S.J.G., B.M.C., K.I., J.C.F., A.B.M., H.C., M.A.S., L.L.L., H.R.F., and M.L.C. have no conflicts of interest. N.B.H. receives unrelated research support from Sanofi and Quidel. J.E.S. has received unrelated research support from Merck.Funding StatementThis study was funded in part by a grant to N.R.P. from the Boston Childrens Hospital Emerging Pathogens and Epidemic Response Cluster of Clinical Research Excellence. S-PLEX assays were provided as an in-kind service by Meso Scale Diagnostics. The U.S. Centers for Disease Control and Prevention funded the referenced Overcoming COVID-19 Immunobiology Study (contracts #75D30119C05584 and #75D30120C07725 to A.G.R.). J.C.F is supported by NIDDK K23DK119463.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Boston Children's Hospital gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors